Molecular studies revealed that the anti-NAFLD effect of DSG might be mediated by the activation of the AMPK/ACC/CPT-1A pathway and inhibition of the SREBP-1c/FAS pathway. This evidence concerns the gene SREBF1 and metabolic dysfunction-associated steatotic liver disease.